Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma ...

New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

For information, the company have advised that they are no longer pursuing a Marketing Authorisation Application from the Medicines and Healthcare products Regulatory Agency (MHRA) for this indication ...

You should read both the consultation document and the accompanying evidence (see the committee papers) before making any comments. You must make your comments ...

We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) ...

This summary report is based on the NICE assumptions used in the resource impact template. Users can amend the 'Inputs and eligible population' and 'Unit costs' worksheets in the template to reflect ...

radioactive iodine has not worked (if it is appropriate), and systemic treatment is needed after sorafenib or lenvatinib. RET-mutant medullary advanced thyroid cancer, if systemic treatment is needed ...

This topic was evaluated as a single technology evaluation by the highly specialised technologies evaluation committee, which is a standing advisory committee of NICE. Committee members are asked to ...

The list price is £2,184 for 56 capsules of 40 mg selpercatinib and £4,368 for 56 capsules of 80 mg (excluding VAT; BNF online accessed August 2024). The company has a commercial arrangement. This ...

There is a commercial access agreement for olaparib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

The recommendations in this guidance represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, health professionals are expected to ...